Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$179.53 USD
+0.06 (0.03%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $179.52 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth A Momentum D VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 33% (82 out of 252)Zacks Sector Rank
Top 38% (6 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.18 | 1.38 | 9.99 |
Current Quarter Estimate | 0.85 | 3.11 | 61.00 |
Year Ago Quarter Estimate | -0.67 | -4.81 | 54.84 |
Next Quarter Estimate | 1.26 | 3.91 | 63.00 |
Next Year Estimate | 7.31 | 24.92 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 186.23 | 17.70 | 15.67 |
Next Year | 207.14 | 9.90 | 11.34 |
Last 5 Years | -265.30 | 0.90 | 8.10 |
Next 5 Years | NA | 22.10 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 345.14 | -6.90 |
Price/Book (MRQ) | 6.15 | 2.05 |
Price/Cash Flow (MRFY) | NA | 16.44 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | 63.73% | -154.18% |
Return on Equity (TTM) | 1.99% | -61.34% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.